Scribe Therapeutics Inc. (Nasdaq: SCTX) announced the pricing of its initial public offering at $15.00 per share for 8,580,000 shares of common stock, a figure that matches the high end of the companys previously indicated range. The company said the offering was upsized and that the gross proceeds are expected to total approximately $128.7 million before underwriting discounts, commissions and other offering expenses, according to its press release.
All offered shares are being sold by Scribe Therapeutics. As part of the deal, the underwriters have been granted a 30-day option to purchase up to an additional 1,287,000 shares at the IPO price, providing potential incremental supply if exercised.
Shares of Scribe Therapeutics were scheduled to begin trading on the Nasdaq Global Market on July 24, 2026. The company indicated the offering is expected to close on July 27, 2026, subject to customary closing conditions.
In a related transaction, Scribe agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi. That private placement is also expected to close on July 27, 2026, subject to customary closing conditions, including the completion of the IPO. The company noted the IPO is not contingent on the private placements closing.
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities are serving as joint book-running managers for the offering.
Scribe Therapeutics develops CRISPR-based genetic medicines. The company said its initial programs are focused on cardiometabolic disease. Scribe also has existing collaborations with Sanofi and Eli Lilly.
Context and implications
The transaction structure includes an upsized primary share sale entirely by the company, a short-term option for underwriters to cover additional demand, and a separate private placement with an existing collaborator. The public listing and concurrent private sale reflect continuing strategic and financing activities tied to the companys CRISPR development programs.